cryptogamesformobile|上市药企海正药业前总裁接受调查！涉贪污受贿、职务侵占等罪，背后牵扯辉瑞制药、高瓴资本

Log in to Sina Finance APP to search [Xinpi] to see more evaluation levels.

News from Red Star Capital Bureau on May 4CryptogamesformobileOn the evening of April 29, Haizheng Pharmaceutical announced that Li Gong, a director and former president of the company, was currently under investigation by relevant departments.

According to the announcement, Haizheng Pharmaceutical Company recently received a letter from the State-owned assets Supervision and Administration Office of the people's Government of Jiaojiang District, Taizhou City. Li Kun, a former director and former president of the company, was suspected of embezzlement, embezzlement, bribery and non-state staff bribery in the company's agency business from 2019 to 2022, and the relevant departments are currently in the process of investigation.

In the latest announcement, Haizheng Pharmaceutical said that at present, the company's production and operation order is normal, the business is advancing steadily, and the daily production and operation activities have not been affected. The company will continue to pay attention to the progress of the above matters and fulfill the obligation of information disclosure in time in strict accordance with the provisions and requirements of relevant laws and regulations.

Former chief executives of listed pharmaceutical companies are investigated

According to public information, Li Gong, male, was born in August 1976, master. He once served as the Director of Business Development of Sigma Aldrich (Shanghai) Trading Co., Ltd., Vice President of Fangyuan Capital, Executive Director and Managing Director of ICBC International financing Capital, Chairman and General Manager of Jilin Boda Pharmaceutical Co., Ltd. Since January 2019, he has been the president of Haizheng Pharmaceutical Co., Ltd.

On April 5, 2023, Li Gou resigned as a director and president of the company for personal reasons, and will no longer hold any position in the company or its subsidiaries after his resignation. According to the financial report, Li Gou received a total pre-tax compensation of 268 in 2022.Cryptogamesformobile.33 million yuan.

During Li Gong's tenure, the main agency business of Haizheng Pharmaceutical Co., Ltd. took place in Hanhui Pharmaceutical, a subsidiary.

Hanhui Pharmaceutical, formerly known as Haizheng Pfizer Pharmaceutical Co., Ltd., was jointly funded by Haizheng Pharmaceutical Co., Ltd. and Pfizer Pharmaceutical Co., Ltd. in September 2012. Due to friction between Haizheng Pharmaceutical and Pfizer over the supply of some products, Haizheng Pharmaceutical announced in November 2017 that Hillhouse Capital would take over some of the shares that Pfizer withdrew after a series of poor performance. In June 2018, Haizheng Huirui officially changed its name to Hanhui Pharmaceutical. After Pfizer quit, it still maintained a cooperative relationship with Hanhui Pharmaceuticals.

Since Hillhouse Capital took over, Hanhui Pharmaceutical's performance has basically maintained slow growth.

Haizheng Pharmaceutical Co., Ltd. spans the pharmaceutical industry, commerce and other sectors, among which Hanhui Pharmaceutical has the strongest profitability and has a significant impact on the company's performance. But after Pfizer withdrew, Hanhui faced the problem of readjusting its strategic direction.

According to the financial report of Haizheng Pharmaceutical Co., Ltd., Hanhui Pharmaceutical's promotion service income comes from self-promotion and agent promotion, the latter being carried out by third-party promotion service providers commissioned by the company, including Fudan Zhangjiang, Novartis, Zaiding Pharmaceutical, etc.

The performance turned into a loss in 2023

Make a profit in the first quarter of this year

According to public data, Haizheng Pharmaceutical was founded in 1956. After more than 60 years of development, it has become a comprehensive pharmaceutical enterprise with the whole value chain of research, production and marketing, the integration of API and preparation, and multi-regional development. The company's sales business covers pharmaceutical preparation-self-management business, pharmaceutical preparation-channel and innovation business, pharmaceutical preparation-investment agency business, pharmaceutical distribution business, pharmaceutical-API business, animal drug business, emerging business.

On April 29, Haizheng Pharmaceutical also released its 2023 annual report and the first quarter report of this year.

Among them, in 2023, the company achieved revenue of 103.Cryptogamesformobile.73 billion yuan, down 13.82% from the same period last yearCryptogamesformobileThe net loss of the parent was 93.1713 million yuan, from profit to loss, down 119.06% from the same period last year. In the first quarter of this year, the company achieved revenue of 2.727 billion yuan, down 11% from the same period last year, while its net profit was 249 million yuan, up 6.99% from the same period last year.

In addition, according to the announcement of Haizheng Pharmaceutical Industry on the same day, the board of directors of the company held a meeting on April 26 and examined and passed the "motion on the appointment of senior managers of the company", and Jiang Ling was appointed as senior vice president and financial director of the company.

The board of directors of the company also agreed that Zhejiang Pharmaceutical Industry Co., Ltd., a wholly-owned subsidiary, would donate 300000 yuan to the Education Foundation of Zhejiang University to support the construction and development of the second Clinical Medical College of Zhejiang University Medical College.

By the end of the first quarter of this year, the total number of shareholders of Haizheng Pharmaceutical Co., Ltd. was 61400.

Source: red Star News